Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Deferred Taxes: 2021-2025

Historic Deferred Taxes for Ironwood Pharmaceuticals (IRWD) over the last 4 years, with Sep 2025 value amounting to $27.8 million.

  • Ironwood Pharmaceuticals' Deferred Taxes rose 261.57% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.7 million, marking a year-over-year increase of 43.47%. This contributed to the annual value of $68.1 million for FY2024, which is 6.26% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Deferred Taxes stood at $27.8 million for Q3 2025, which was up 96.89% from $14.1 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Deferred Taxes peaked at $41.1 million during Q4 2024, and registered a low of $670,000 during Q1 2025.
  • For the 3-year period, Ironwood Pharmaceuticals' Deferred Taxes averaged around $16.7 million, with its median value being $14.1 million (2025).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Deferred Taxes skyrocketed by 941.33% in 2022, and later slumped by 88.93% in 2025.
  • Ironwood Pharmaceuticals' Deferred Taxes (Quarterly) stood at $1.9 million in 2021, then surged by 941.33% to $20.1 million in 2022, then surged by 55.60% to $31.3 million in 2023, then skyrocketed by 31.23% to $41.1 million in 2024, then spiked by 261.57% to $27.8 million in 2025.
  • Its last three reported values are $27.8 million in Q3 2025, $14.1 million for Q2 2025, and $670,000 during Q1 2025.